Atopic dermatitis: an expanding therapeutic pipeline for a complex disease

T Bieber - Nature reviews Drug discovery, 2022 - nature.com
Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex
pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains …

[HTML][HTML] Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council

Y Renert-Yuval, JP Thyssen, R Bissonnette… - Journal of Allergy and …, 2021 - Elsevier
Atopic dermatitis (AD) is a common yet complex skin disease, posing a therapeutic
challenge with increasingly recognized different phenotypes among variable patient …

An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging

N Sayed, Y Huang, K Nguyen, Z Krejciova-Rajaniemi… - Nature aging, 2021 - nature.com
While many diseases of aging have been linked to the immunological system, immune
metrics capable of identifying the most at-risk individuals are lacking. From the blood …

Update on the pathogenesis and therapy of atopic dermatitis

H Li, Z Zhang, H Zhang, Y Guo, Z Yao - Clinical reviews in allergy & …, 2021 - Springer
Atopic dermatitis (AD) is a common inflammatory skin disorder characterized by recurrent
eczematous lesions and intense itch. Although it most often starts in infancy and affects …

Interleukin‐13: targeting an underestimated cytokine in atopic dermatitis

T Bieber - Allergy, 2020 - Wiley Online Library
Atopic dermatitis (AD) is a common inflammatory skin condition that has traditionally been
considered a paradigmatic type 2 immunity (T2)‐driven disease. Interleukin (IL)‐4 and IL‐13 …

Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial

E Guttman-Yassky, A Blauvelt, LF Eichenfield… - JAMA …, 2020 - jamanetwork.com
Importance Interleukin 13 (IL-13) is a central pathogenic mediator driving multiple features of
atopic dermatitis (AD) pathophysiology. Objective To evaluate the efficacy and safety of …

Disease modification in inflammatory skin disorders: opportunities and challenges

T Bieber - Nature Reviews Drug Discovery, 2023 - nature.com
Progress in understanding of the mechanisms underlying chronic inflammatory skin
disorders, such as atopic dermatitis and psoriasis vulgaris, has led to new treatment options …

The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults

Y Renert-Yuval, E Del Duca, AB Pavel, M Fang… - Journal of Allergy and …, 2021 - Elsevier
Background Although atopic dermatitis (AD) often presents in infancy and persists into
adulthood, comparative characterization of AD skin among different pediatric age groups is …

Multiple roles for cytokines in atopic dermatitis: from pathogenic mediators to endotype-specific biomarkers to therapeutic targets

L Fania, G Moretta, F Antonelli, E Scala… - International Journal of …, 2022 - mdpi.com
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases, which
generally presents with intense itching and recurrent eczematous lesions. AD affects up to …

The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature

AB Pavel, L Zhou, A Diaz, B Ungar, J Dan, H He… - Journal of the American …, 2020 - Elsevier
Background Moderate-to-severe atopic dermatitis (AD) is increasingly recognized as a
systemic disease, largely due to proteomic blood studies. There are growing efforts to …